DxBio specializes in advanced diagnostic tools that enhance research capabilities.
DxBio is a next-generation diagnostics company combining CRISPR-based assays, AI analytics and microfluidic automation to detect antimicrobial resistance (AMR) and early pathogen threats with speed, precision and affordability. dxbio.ai
.png)
Need:
AMR is a major global health threat; traditional diagnostics are too slow or insensitive to timely detect resistance patterns.
Solution:
DxBio deploys CRISPR-powered detection combined with AI to identify AMR markers rapidly and accurately, enabling timely interventions and reducing spread.
Need:
Many labs rely on slow culturing methods or manual assays, limiting throughput and scalability.
Solution:
DxBio integrates microfluidics automation and AI-driven data analysis to scale diagnostics, reduce human bottlenecks, and increase accessibility of AMR testing in real-world settings.
Need:
Effective diagnostics are often cost-prohibitive or inaccessible in resource-constrained settings, hampering public-health efforts.
Solution:
DxBio designs its platform to be cost-effective, rapid and scalable — broadening access to advanced AMR diagnostics globally.
1.Modular approach for customizable, cohesive solutions
2.Automated workflows and claims processing
3.Reduced administrative complexity
4.Unified care delivery across systems
5.High security and compliance standards
6.Supports healthcare providers in optimizing care delivery and patient outcomes